-
The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesotheliomaErčulj, Nina ...Objective: Identification of biomarkers that could predict gemcitabine efficacy and toxicity is a key issue in the development of individualized therapy. The aim of our study was to evaluate the ... influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma (MM). Methods: In total, 107 patients with MM, treated with gemcitabine-platinum chemotherapy, were genotyped for 11 polymorphisms in deoxycytidine kinase, ribonucleotide reductase M1 (RRM1), and cytidine deaminase genes using KASPar assays. Binary logistic regression was used to evaluate the influence of selected polymorphisms on tumor response and occurrence of treatment-related toxicity, while their influence on survival was estimated by Cox proportional hazards model. A haplotype analysis was carried out to assess the combined effect of RRM1 polymorphisms. Results: Deoxycytidine kinase and cytidine deaminase polymorphisms did not influence treatment outcome in patients with MM. In multivariable analysis, RRM1 2927A>Cpolymorphism significantly decreased overall survival probability šhazard ratio (HR)=2.02; 95% confidence interval (CI)=1.11-3.65; P=0.021đ. Twopromoter polymorphisms, RRM1 -524T>C and -37C>A, decreased the odds of nausea/vomiting grade>/=2 occurrence šodds ratio (OR)=0.25; 95% CI=0.10-0.60; P=0.002 and OR=0.26; 95% CI=0.11-0.63; P=0.003, respectivelyđ. RRM1 TTCCA haplotype was associated with worse tumor response (OR=16.67; 95% CI=2.38-100.00; P=0.004) and worse overall survival (HR=2.97; 95% CI=1.46-6.06; P=0.003) compared with the most frequent TTCAA haplotype, while TCACA haplotype influenced nausea/vomiting grade>/=2 occurrence (OR=0.27; 95% CI=0.12-0.60; P=0.001). Conclusion: RRM1 polymorphisms as well as haplotypes showed an association with gemcitabine treatment efficacy and toxicity; therefore, they should be validated as potential markers for the prediction ofclinical outcome in patients with MM.Vir: Pharmacogenetics and genomics. - ISSN 1744-6872 (Vol. 22, iss. 1, 2012, str. 58-68)Vrsta gradiva - članek, sestavni delLeto - 2012Jezik - angleškiCOBISS.SI-ID - 29194201
Avtor
Erčulj, Nina |
Kovač, Viljem |
Hmeljak, Julija |
Franko, Alenka |
Dodič-Fikfak, Metoda |
Dolžan, Vita
Teme
Pleural neoplasms |
Mesothelioma |
Drug therapy |
Platinum |
Deoxycytidine |
Genotype |
Haplotypes |
Treatment outcome |
Deoxycytidine kinase |
Ribonucleotide reductases |
Cytidine deaminase |
Survival analysis |
Regression analysis |
Proportional hazards models |
Prsna mrena, novotvorbe |
Genotip |
Mezoteliom |
Deoksicitidin |
Platina |
Preživetje, analiza |
Proporcionalni modeli tveganja |
Ribonukleotidne reduktaze |
Deoksicitidinska kinaza |
Citidinska deaminaza |
Zdravljenje, izid |
Regresijska analiza |
Haplotipi
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Erčulj, Nina | 30705 |
Kovač, Viljem | 16229 |
Hmeljak, Julija | 29479 |
Franko, Alenka | 23759 |
Dodič-Fikfak, Metoda | 12218 |
Dolžan, Vita | 11711 |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.